Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LAS41004 IMP6 is an investigational topical ointment formulation developed by Almirall for the treatment of mild to moderate plaque psoriasis. It is a fixed-dose combination of bexarotene, a selective retinoid X receptor (RXR) agonist, and betamethasone dipropionate, a potent corticosteroid. The combination is designed to provide synergistic effects by targeting both the inflammatory pathways (via the corticosteroid) and the cellular differentiation/proliferation pathways (via the retinoid) involved in psoriasis. The 'IMP6' designation refers to a specific formulation variant tested in Phase 2 clinical trials, including the Psoriasis Plaque Test (PPT), to evaluate its anti-psoriatic efficacy and safety profile, particularly regarding skin atrophy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LAS41004 IMP6.